US firm Covington & Burling has taken the lead role for pharma giant GlaxoSmithKline (GSK) on its record $3bn (£1.9bn) criminal and civil settlement over drug misbranding, reports The Blog of Legal Times.
The settlement saw GSK agree to plead guilty to criminal charges and to pay $1bn (£638m) in criminal fines and forfeitures for the illegal marketing and promotion of the drugs Paxil and Wellbutrin.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
